“Significant challenges remain in the high-cost, lengthy processes to develop new drugs and bring them to market,” says Arsenal Capital Partners‘ Jeff Kovach in this Q&A with Mergers & Acquisitions. “Technology-enabled solutions to tackle some of these challenges will be highly sought after in the market.”
Buyers are attracted to businesses and technologies focused on developing vaccines, conducting clinical trial research and delivering telehealth services. One private equity firm involved in the sector is Arsenal Capital Partners. Mergers & Acquisitions spoke with Arsenal managing partner Jeff Kovach about the firm’s investment strategy and other mid-market deal opportunities.
Tell us about Arsenal’s investment strategy.
To read the entire story, you must be logged in.
Please log in now or register with us.
